Health News Releases

  • Today December 7
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
December 05, 17:15
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance o
December 05, 15:40
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU
December 05, 14:15
Parse Biosciences Launches Evercode Whole Blood Fixation
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixati
Deanna Kelly, PharmD, BCPP, Live It, Launch It program lead
December 05, 11:20
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health
Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in
December 05, 11:00
Famenity's Brain Factor-7® Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health
Famenity Co., Ltd. (https://famenity.com/home-en/), a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®)
December 04, 15:09
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive o
November 27, 16:00
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines Ltd (https://beonemedicines.com/). (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and
November 26, 16:20
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (3
November 25, 09:40
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, c
November 23, 11:30
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54361159&newsitemid=20251120303213&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding te
November 21, 14:20
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round wa
The main entrance of K2 MEDITECH headquarters, representing the company’s commitment to innovation a
November 21, 14:07
K2 MEDITECH Sets a New Benchmark in the Global Skin Booster Market
Built on innovative skin-regeneration technology, K2 MEDITECH is rapidly gaining attention in the global beauty and medical aesthetics industries. As a specialized manufacturer of skin boosters, th
November 20, 15:10
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraff
November 20, 15:00
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial e
SPARK Headquarters (SPARK HQ) (Photo: AETOSWire)
November 20, 13:30
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D
In the United Arab Emirates, where cities like Abu Dhabi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fu.ae%2Fen%2Fabout-the-uae%2Fthe-seven-emirates%2FAbu-Dhabi&esheet=54359920&n
November 18, 16:06
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This progra
November 18, 15:10
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pert
November 17, 15:50
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatolog
November 16, 13:40
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune Disease
Third Rock Ventures and Parse Biosciences today announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs) using Parse Biosciences’ GigaLab platform. The
Bernard Tannoury, President of Benta SAS, and Sohail Zaidi, CEO of Ananda Scientific Inc., signing t
November 16, 13:25
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understandin
November 14, 15:10
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play de
November 13, 14:50
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma
The U.S. Food and Drug Administration (FDA) has approved the Promega (https://bit.ly/4nUmP66) OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatelli
November 13, 10:55
InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
InterSystems (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.intersystems.com%2F&esheet=54356186&newsitemid=20251112864064&lan=en-US&anchor=InterSystems&index=1&md5=a79330a679c0
Qorium is successfully producing sustainable real leather
November 12, 16:25
Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation
Qorium, the Dutch biotechnology company pioneering cultivated leather, today announced it has secured a €22 million investment from Invest-NL and LIOF alongside existing investors Brightlands Venture
November 12, 10:40
Prokarium Appoints Ibs Mahmood as Chief Executive Officer
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kri
Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to h
November 11, 16:20
Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms
Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexL
November 10, 15:40
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of
November 10, 10:15
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered
November 09, 09:50
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54353741&newsitemid=20251107689017&lan=en-US&anchor=TSE%3A4
NJ Bio, Inc. now offers translational research services after completing asset purchase and full int
November 07, 11:30
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Res
Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncolog
November 07, 10:10
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreeme
November 07, 09:50
Merz Aesthetics® Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only FDA-Cleared Ultrasound With Real-Time Visualization
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the U.S. Food and Drug Administration (FDA) clearance of Ultherapy PRIME to improve the appearance of skin l
November 05, 16:10
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for augment
November 05, 11:50
Merz Aesthetics® Introduces New BELOTERO® Syringe Offering Greater Precision, Comfort and Ease of Use
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe i
November 04, 08:39
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54348492&newsitemid=20251030478402&lan=en-US&anchor=TSE%3A4
Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings,
November 03, 11:44
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Sams
October 31, 10:40
Novotech Maps Global Growth in Radiopharmaceutical Trials
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, today released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research a
October 31, 10:15
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China
October 30, 16:51
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54345580&newsitemid=20251029831616&lan=en-US&anc
October 30, 16:30
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2025-Enterprise-Press-Release-1025&utm_medium=pressrelease&utm_source=prnews&utm_content=SSNC-AI-Agents) (Nasdaq: SSNC) today
October 30, 16:20
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual,
ONEWAYLAB team member demonstrating the company’s flagship device to visitors at the Beautyworld Mid
October 30, 13:52
ONEWAYLAB Expands Global Presence with Cutting-Edge Beauty Tech at Beautyworld Middle East 2025
ONEWAYLAB Co., Ltd. announced its participation in Beautyworld Middle East 2025, one of the world’s leading exhibitions for the beauty and wellness industries, held in Dubai. Certified as an offici
October 30, 09:00
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live - jslm). To date, more than five thousand patients suffer
October 29, 10:55
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green La
Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vin
October 28, 15:30
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy - Technology Transferred from Japan
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy (https://www.immunotreatment.org/), utilizing patients'
Signing ceremony for the exclusive distribution agreement of the Wholemom artificial insemination so
October 27, 08:00
NURI SCIENCE Expands into Latin American Market through Exclusive Partnership in Paraguay
NURI SCIENCE Inc., a biotechnology company specializing in livestock reproduction technology, has signed an exclusive distribution agreement with Buenos Negocios S.A., a leading agricultural and lives
FACTS Logo
October 26, 11:15
Berry Consultants Releases FACTS 8 Clinical Trial Simulator
Berry Consultants, LLC announced the release of FACTS 8 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.berryconsultants.com%2Fsoftware%2Fchangelog&esheet=54344231&newsitemid=20
October 24, 15:50
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for “Bubble Baby Disease”
AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity’s gene therap
October 23, 17:35
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54341613&newsitemid=20251020512177&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
October 23, 16:58
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commerci
October 23, 15:00
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share
Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (“Blackstone”) and TPG in a transaction valued at up to $79 p
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital
October 23, 14:10
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, today a
HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics
October 23, 11:40
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54343102&newsitemid=20251022130560&lan=en-US&anchor=HistoSonics&index=1&md5=40fd847d883559ad8d0
Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park
October 22, 17:15
Rigaku opens Rigaku Technology Center Taiwan
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a ne
Ferrer’s pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain.
October 22, 15:55
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and ph
Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients
October 22, 15:15
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award (https://baszuckigroup.com/metabolic-psychiatry-scholar-award/), a new initiative that suppo
October 22, 14:50
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54343084&newsitemid=20251021006409&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Photo credit: IFF
October 22, 11:10
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and le
Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of
October 21, 09:45
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entere
October 20, 15:07
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth f
October 19, 16:02
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimul
HistoSonics Announces Oversubscribed $250 Million Growth Financing
October 17, 14:50
HistoSonics Announces Oversubscribed $250 Million Growth Financing
HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new owners
Credits to Roquette
October 17, 14:15
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharm
October 16, 16:15
SS&C Technologies Completes Acquisition of Calastone
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2025-Enterprise-Press-Release-1025%26utm_medium%3Dpressreleas
October 15, 11:45
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54337814&newsitemid=20251013125479&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
October 14, 11:40
Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54336442&newsitemid=20251009983648&lan=en-US&anchor=Parse+Biosciences&index=1&md
Pictured (L-R): Heidi co-founders Waleed Mussa, CFO; Dr. Thomas Kelly, CEO; and Yu Liu, CTO.
October 12, 13:00
Heidi Secures $65 Million USD in Series B Funding to Accelerate Building an AI Care Partner for Every Clinician
Heidi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heidihealth.com%2F&esheet=54334156&newsitemid=20251005012225&lan=en-US&anchor=Heidi&index=1&md5=660ced366440a0565290ef7747c
October 12, 11:00
Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)
Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind
A pharmacist advises a consumer on the purchase of Haleon’s Otrivin nasal mist.
October 12, 10:30
Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI
Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce
October 10, 17:20
Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept s
October 10, 16:55
Tempus Joins Parse Biosciences’ Certified Service Provider Network
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54333556&newsitemid=20251008146500&lan=en-US&anchor=Parse+Biosciences&index=1&md5
Masimo SET® Pulse Oximetry and RD SET® Sensors
October 10, 14:40
In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones
Masimo (https://www.masimo.com/) (NASDAQ: MASI) today announced the findings of an exploratory analysis for a unique feasibility study published in CHEST Critical Care in which Dr. Andrew Goodwin and
October 10, 11:10
TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III
TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors an
October 05, 11:55
Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments
Kinaxis® (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54333058&newsitemid=20251002088321&lan=en-US&anchor=Kinaxis%26%23174%3B&index=1&md5=bc238f272987
October 05, 11:40
Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
Neuraptive Therapeutics, Inc., a biotechnology company focused on developing novel therapies to improve outcomes in peripheral nerve injuries (PNI), today announced the first patient has been enrolled
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
October 02, 14:50
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced the launch of WHOOP Advanced Labs (https://www.whoop.com/kr/en/advanced-labs/), a groundbreaking new feature that c
October 02, 14:50
Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health
Dentalis Animal Health Inc. is proud to announce a landmark achievement in veterinary dentistry: the company has been awarded five prestigious Veterinary Oral Health Council (VOHC®) Seals of Approval,
October 02, 11:10
Parse Biosciences Expands Global Access by Certifying Single Cell Discoveries as a Service Provider
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54330033&newsitemid=20250930263922&lan=en-US&anchor=Parse+Biosciences&index=1&md5
October 01, 15:35
Microplastics in the Air: Global Study Uncovers Concerning Levels of Daily Exposure
The PlasticDustCloud project, a global study led by the Eurofins Environment Testing network, has revealed alarming microplastic pollution in air, with deposition rates of up to 1,300 microplastics pe
September 24, 16:10
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from
September 24, 15:30
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform
September 24, 09:32
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment t
September 18, 14:40
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™
September 18, 14:25
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54324636&newsitemid=20250917266545&lan=en-US&anchor=Masimo&index=1&md5=1c2d4fc2fd80ea476e53a7e74df69244)
September 18, 13:55
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. Ne
September 17, 16:10
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental facto
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single
September 17, 10:05
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technolo
September 17, 08:59
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the
September 16, 17:35
FrieslandCampina Ingredients Expands R&D Capabilities with New State-of-the-Art Application Centre in Singapore
FrieslandCampina Ingredients, a global leader in proteins and prebiotics, has announced the opening of a new application centre in Singapore, representing a 30% increase of R&D space in the city-state
Group photo of representatives from MEDIPEAU Inc. and GNPharm at the conference venue
September 16, 14:00
MEDIPEAU Showcases its Film-Type Wound Dressing Cream at 51st Annual Fall Meeting of Korean Pediatric Association
MEDIPEAU Inc., a company specializing in therapeutic solutions for atopic dermatitis, introduced its groundbreaking “BARRICURE Aid Film MD” during the 51st Annual Fall Meeting of the Korean Pediatric
September 16, 09:45
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas
Helmholtz Munich and Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54323217&newsitemid=20250915189668&lan=en-US&anchor=Parse+Bi
RPTs: Pre-clinical Drug Discovery Pipeline
September 12, 16:20
Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation
Medicines Discovery Catapult (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmd.catapult.org.uk%2F&esheet=54321838&newsitemid=20250911458780&lan=en-US&anchor=Medicines+Discovery+Cat
September 12, 15:20
Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec
Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on August 27th, 2025. This non-replicating gene therapy, ad
Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire)
September 12, 13:35
Nominations Open for Fifth Edition of Aster Guardians Global Nursing Award 2026 Worth USD 250,000
Aster DM Healthcare has announced the launch of the fifth edition of the Aster Guardians Global Nursing Award, one of the world’s most prominent recognition for nursing excellence worth USD 250,000.
September 12, 10:55
Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase
Promega Corporation (https://www.promega.kr/?utm_source=businesswire.com&utm_medium=referral&utm_campaign=%28referral%29) has entered a strategic partnership with Watchmaker Genomics (https://www.watc
September 11, 15:50
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress, taking pla
September 10, 16:30
Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare mar
September 10, 16:00
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory m
September 08, 17:39
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54319980&newsitemid=20250908503054&lan=en-US&ancho
September 07, 16:11
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Rec
25 per page50 per page75 per page100 per page